Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 3774 entries
Sorted by: Best Match Show Resources per page
Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity.

Chembiochem : a European journal of chemical biology

Gade M, Alex C, Leviatan Ben-Arye S, Monteiro JT, Yehuda S, Lepenies B, Padler-Karavani V, Kikkeri R.
PMID: 29575424
Chembiochem. 2018 Mar 25; doi: 10.1002/cbic.201800037. Epub 2018 Mar 25.

Carbohydrate-protein interactions (CPIs) are involved in a wide range of biological phenomena. Hence, the characterization and presentation of carbohydrate epitopes that closely mimic the natural environment is one of the long-term goals of glycosciences. Inspired by the multivalency, heterogeneity...

Cite
Gade M, Alex C, Leviatan Ben-Arye S, et al. Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity. Chembiochem. 2018;doi: 10.1002/cbic.201800037.
Gade, M., Alex, C., Leviatan Ben-Arye, S., Monteiro, J. T., Yehuda, S., Lepenies, B., Padler-Karavani, V., & Kikkeri, R. (2018). Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity. Chembiochem : a European journal of chemical biology, . https://doi.org/10.1002/cbic.201800037
Gade, Madhuri, et al. "Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity." Chembiochem : a European journal of chemical biology vol. (2018). doi: https://doi.org/10.1002/cbic.201800037
Gade M, Alex C, Leviatan Ben-Arye S, Monteiro JT, Yehuda S, Lepenies B, Padler-Karavani V, Kikkeri R. Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity. Chembiochem. 2018 Mar 25; doi: 10.1002/cbic.201800037. Epub 2018 Mar 25. PMID: 29575424; PMCID: PMC6949124.
Copy Download .nbib Format: NLM
Construction and Characterization of Recombinant HEK Cell Over Expressing α4 Integrin.

Advanced pharmaceutical bulletin

Naderi Beni S, Kouhpayeh S, Hejazi Z, Heidari Hafshejani N, Khanahmad H.
PMID: 26504766
Adv Pharm Bull. 2015 Sep;5(3):429-34. doi: 10.15171/apb.2015.058. Epub 2015 Sep 19.

PURPOSE: Integrins are heterodimeric membrane proteins, which are exposed to post translational modifications in eukaryotic cells in contrast to prokaryotic cells. These modifications provide advantages for production of proper nanobody, mono and polyclonal antibody against this surface protein and...

Cite
Naderi Beni S, Kouhpayeh S, Hejazi Z, et al. Construction and Characterization of Recombinant HEK Cell Over Expressing α4 Integrin. Adv Pharm Bull. 2015;5(3):429-34doi: 10.15171/apb.2015.058.
Naderi Beni, S., Kouhpayeh, S., Hejazi, Z., Heidari Hafshejani, N., & Khanahmad, H. (2015). Construction and Characterization of Recombinant HEK Cell Over Expressing α4 Integrin. Advanced pharmaceutical bulletin, 5(3), 429-34. https://doi.org/10.15171/apb.2015.058
Naderi Beni, Shamsi, et al. "Construction and Characterization of Recombinant HEK Cell Over Expressing α4 Integrin." Advanced pharmaceutical bulletin vol. 5,3 (2015): 429-34. doi: https://doi.org/10.15171/apb.2015.058
Naderi Beni S, Kouhpayeh S, Hejazi Z, Heidari Hafshejani N, Khanahmad H. Construction and Characterization of Recombinant HEK Cell Over Expressing α4 Integrin. Adv Pharm Bull. 2015 Sep;5(3):429-34. doi: 10.15171/apb.2015.058. Epub 2015 Sep 19. PMID: 26504766; PMCID: PMC4616894.
Copy Download .nbib Format: NLM
Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Nature

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U.
PMID: 26040715
Nature. 2015 Jul 16;523(7560):370. doi: 10.1038/nature14567. Epub 2015 Jun 03.

No abstract available.

Cite
Kreiter S, Vormehr M, van de Roemer N, et al. Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;523(7560):370doi: 10.1038/nature14567.
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, �. �., & Sahin, U. (2015). Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 523(7560), 370. https://doi.org/10.1038/nature14567
Kreiter, Sebastian, et al. "Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer." Nature vol. 523,7560 (2015): 370. doi: https://doi.org/10.1038/nature14567
Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U. Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015 Jul 16;523(7560):370. doi: 10.1038/nature14567. Epub 2015 Jun 03. PMID: 26040715.
Copy Download .nbib Format: NLM
Grouping of large populations into few CTL immune 'response-types' from influenza H1N1 genome analysis.

Clinical & translational immunology

Mukherjee S, Chandra N.
PMID: 25505972
Clin Transl Immunology. 2014 Aug 08;3(8):e24. doi: 10.1038/cti.2014.17. eCollection 2014 Aug.

Despite extensive work on influenza, a number of questions still remain open about why individuals are differently susceptible to the disease and why only some strains lead to epidemics. Here we study the effect of human leukocyte antigen (HLA)...

Cite
Mukherjee S, Chandra N. Grouping of large populations into few CTL immune 'response-types' from influenza H1N1 genome analysis. Clin Transl Immunology. 2014;3(8):e24doi: 10.1038/cti.2014.17.
Mukherjee, S., & Chandra, N. (2014). Grouping of large populations into few CTL immune 'response-types' from influenza H1N1 genome analysis. Clinical & translational immunology, 3(8), e24. https://doi.org/10.1038/cti.2014.17
Mukherjee, Sumanta, and Chandra, Nagasuma. "Grouping of large populations into few CTL immune 'response-types' from influenza H1N1 genome analysis." Clinical & translational immunology vol. 3,8 (2014): e24. doi: https://doi.org/10.1038/cti.2014.17
Mukherjee S, Chandra N. Grouping of large populations into few CTL immune 'response-types' from influenza H1N1 genome analysis. Clin Transl Immunology. 2014 Aug 08;3(8):e24. doi: 10.1038/cti.2014.17. eCollection 2014 Aug. PMID: 25505972; PMCID: PMC4232073.
Copy Download .nbib Format: NLM
Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins.

Frontiers in immunology

Agallou M, Athanasiou E, Koutsoni O, Dotsika E, Karagouni E.
PMID: 24959167
Front Immunol. 2014 Jun 10;5:268. doi: 10.3389/fimmu.2014.00268. eCollection 2014.

Leishmaniasis is a significant worldwide health problem for which no vaccine exists. Activation of CD4(+) and CD8(+) T cells is crucial for the generation of protective immunity against parasite. Recent trend in vaccine design has been shifted to epitope-based...

Cite
Agallou M, Athanasiou E, Koutsoni O, et al. Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins. Front Immunol. 2014;5:268doi: 10.3389/fimmu.2014.00268.
Agallou, M., Athanasiou, E., Koutsoni, O., Dotsika, E., & Karagouni, E. (2014). Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins. Frontiers in immunology, 5268. https://doi.org/10.3389/fimmu.2014.00268
Agallou, Maria, et al. "Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins." Frontiers in immunology vol. 5 (2014): 268. doi: https://doi.org/10.3389/fimmu.2014.00268
Agallou M, Athanasiou E, Koutsoni O, Dotsika E, Karagouni E. Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins. Front Immunol. 2014 Jun 10;5:268. doi: 10.3389/fimmu.2014.00268. eCollection 2014. PMID: 24959167; PMCID: PMC4051127.
Copy Download .nbib Format: NLM
Dengue: challenges for policy makers and vaccine developers.

Current infectious disease reports

Wilder-Smith A, Macary P.
PMID: 24781826
Curr Infect Dis Rep. 2014 May;16(5):404. doi: 10.1007/s11908-014-0404-2.

Because of the increasing incidence, geographic expansion and economic burden of dengue transmission, dengue poses major challenges to policy makers. A vaccine against dengue is urgently needed, but vaccine development has been hampered by the lack of an appropriate...

Cite
Wilder-Smith A, Macary P. Dengue: challenges for policy makers and vaccine developers. Curr Infect Dis Rep. 2014;16(5):404doi: 10.1007/s11908-014-0404-2.
Wilder-Smith, A., & Macary, P. (2014). Dengue: challenges for policy makers and vaccine developers. Current infectious disease reports, 16(5), 404. https://doi.org/10.1007/s11908-014-0404-2
Wilder-Smith, Annelies, and Macary, Paul. "Dengue: challenges for policy makers and vaccine developers." Current infectious disease reports vol. 16,5 (2014): 404. doi: https://doi.org/10.1007/s11908-014-0404-2
Wilder-Smith A, Macary P. Dengue: challenges for policy makers and vaccine developers. Curr Infect Dis Rep. 2014 May;16(5):404. doi: 10.1007/s11908-014-0404-2. PMID: 24781826; PMCID: PMC4024152.
Copy Download .nbib Format: NLM
Prediction of an Epitope-based Computational Vaccine Strategy for Gaining Concurrent Immunization Against the Venom Proteins of Australian Box Jellyfish.

Toxicology international

Alam MJ, Ashraf KU.
PMID: 24403734
Toxicol Int. 2013 Sep;20(3):235-53. doi: 10.4103/0971-6580.121677.

BACKGROUND: Australian Box Jellyfish (C. fleckeri) has the most rapid acting venom known to in the arena of toxicological research and is capable enough of killing a person in less than 5 minutes inflicting painful, debilitating and potentially life-threatening...

Cite
Alam MJ, Ashraf KU. Prediction of an Epitope-based Computational Vaccine Strategy for Gaining Concurrent Immunization Against the Venom Proteins of Australian Box Jellyfish. Toxicol Int. 2013;20(3):235-53doi: 10.4103/0971-6580.121677.
Alam, M. J., & Ashraf, K. U. (2013). Prediction of an Epitope-based Computational Vaccine Strategy for Gaining Concurrent Immunization Against the Venom Proteins of Australian Box Jellyfish. Toxicology international, 20(3), 235-53. https://doi.org/10.4103/0971-6580.121677
Alam, Md Jibran, and Ashraf, Kutub Uddin Muhammad. "Prediction of an Epitope-based Computational Vaccine Strategy for Gaining Concurrent Immunization Against the Venom Proteins of Australian Box Jellyfish." Toxicology international vol. 20,3 (2013): 235-53. doi: https://doi.org/10.4103/0971-6580.121677
Alam MJ, Ashraf KU. Prediction of an Epitope-based Computational Vaccine Strategy for Gaining Concurrent Immunization Against the Venom Proteins of Australian Box Jellyfish. Toxicol Int. 2013 Sep;20(3):235-53. doi: 10.4103/0971-6580.121677. PMID: 24403734; PMCID: PMC3877492.
Copy Download .nbib Format: NLM
Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome.

Frontiers in immunology

Oliveira CC, van Hall T.
PMID: 26097483
Front Immunol. 2015 Jun 05;6:298. doi: 10.3389/fimmu.2015.00298. eCollection 2015.

The well described conventional antigen-processing pathway is accountable for most peptides that end up in MHC class I molecules at the cell surface. These peptides experienced liberation by the proteasome and transport by the peptide transporter TAP. However, there...

Cite
Oliveira CC, van Hall T. Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome. Front Immunol. 2015;6:298doi: 10.3389/fimmu.2015.00298.
Oliveira, C. C., & van Hall, T. (2015). Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome. Frontiers in immunology, 6298. https://doi.org/10.3389/fimmu.2015.00298
Oliveira, Cláudia C, and van Hall, Thorbald. "Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome." Frontiers in immunology vol. 6 (2015): 298. doi: https://doi.org/10.3389/fimmu.2015.00298
Oliveira CC, van Hall T. Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome. Front Immunol. 2015 Jun 05;6:298. doi: 10.3389/fimmu.2015.00298. eCollection 2015. PMID: 26097483; PMCID: PMC4457021.
Copy Download .nbib Format: NLM
GB Virus C/Hepatitis G Virus Envelope Glycoprotein E2: Computational Molecular Features and Immunoinformatics Study.

Hepatitis monthly

Ranjbar MM, Ghorban K, Alavian SM, Keyvani H, Dadmanesh M, Roayaei Ardakany A, Motedayen MH, Sazmand A.
PMID: 24403917
Hepat Mon. 2013 Dec 30;13(12):e15342. doi: 10.5812/hepatmon.15342.

INTRODUCTION: GB virus C (GBV-C) or hepatitis G virus (HGV) is an enveloped, RNA positive-stranded flavivirus-like particle. E2 envelope protein of GBV-C plays an important role in virus entry into the cytosol, genotyping and as a marker for diagnosing...

Cite
Ranjbar MM, Ghorban K, Alavian SM, et al. GB Virus C/Hepatitis G Virus Envelope Glycoprotein E2: Computational Molecular Features and Immunoinformatics Study. Hepat Mon. 2013;13(12):e15342doi: 10.5812/hepatmon.15342.
Ranjbar, M. M., Ghorban, K., Alavian, S. M., Keyvani, H., Dadmanesh, M., Roayaei Ardakany, A., Motedayen, M. H., & Sazmand, A. (2013). GB Virus C/Hepatitis G Virus Envelope Glycoprotein E2: Computational Molecular Features and Immunoinformatics Study. Hepatitis monthly, 13(12), e15342. https://doi.org/10.5812/hepatmon.15342
Ranjbar, Mohammad Mahdi, et al. "GB Virus C/Hepatitis G Virus Envelope Glycoprotein E2: Computational Molecular Features and Immunoinformatics Study." Hepatitis monthly vol. 13,12 (2013): e15342. doi: https://doi.org/10.5812/hepatmon.15342
Ranjbar MM, Ghorban K, Alavian SM, Keyvani H, Dadmanesh M, Roayaei Ardakany A, Motedayen MH, Sazmand A. GB Virus C/Hepatitis G Virus Envelope Glycoprotein E2: Computational Molecular Features and Immunoinformatics Study. Hepat Mon. 2013 Dec 30;13(12):e15342. doi: 10.5812/hepatmon.15342. PMID: 24403917; PMCID: PMC3877655.
Copy Download .nbib Format: NLM
Dynamic interactions of neutrophils and biofilms.

Journal of oral microbiology

Hirschfeld J.
PMID: 25523872
J Oral Microbiol. 2014 Dec 17;6:26102. doi: 10.3402/jom.v6.26102. eCollection 2014.

BACKGROUND: The majority of microbial infections in humans are biofilm-associated and difficult to treat, as biofilms are highly resistant to antimicrobial agents and protect themselves from external threats in various ways. Biofilms are tenaciously attached to surfaces and impede...

Cite
Hirschfeld J. Dynamic interactions of neutrophils and biofilms. J Oral Microbiol. 2014;6:26102doi: 10.3402/jom.v6.26102.
Hirschfeld, J. (2014). Dynamic interactions of neutrophils and biofilms. Journal of oral microbiology, 626102. https://doi.org/10.3402/jom.v6.26102
Hirschfeld, Josefine. "Dynamic interactions of neutrophils and biofilms." Journal of oral microbiology vol. 6 (2014): 26102. doi: https://doi.org/10.3402/jom.v6.26102
Hirschfeld J. Dynamic interactions of neutrophils and biofilms. J Oral Microbiol. 2014 Dec 17;6:26102. doi: 10.3402/jom.v6.26102. eCollection 2014. PMID: 25523872; PMCID: PMC4270880.
Copy Download .nbib Format: NLM
The clinical potential of circulating tumor cells; the need to incorporate a modern "immunological cocktail" in the assay.

Cancers

Uhr JW.
PMID: 24351672
Cancers (Basel). 2013 Dec 13;5(4):1739-47. doi: 10.3390/cancers5041739.

The accepted clinical assay, CellSearch®, and lab-on-a-chip tests for capturing circulating tumor cells are antibody-mediated. Attempts to improve their sensitivity have relied upon physical changes in the instruments. There have been no significant advances in improving the antibody-mediated portion...

Cite
Uhr JW. The clinical potential of circulating tumor cells; the need to incorporate a modern "immunological cocktail" in the assay. Cancers (Basel). 2013;5(4):1739-47doi: 10.3390/cancers5041739.
Uhr, J. W. (2013). The clinical potential of circulating tumor cells; the need to incorporate a modern "immunological cocktail" in the assay. Cancers, 5(4), 1739-47. https://doi.org/10.3390/cancers5041739
Uhr, Jonathan W. "The clinical potential of circulating tumor cells; the need to incorporate a modern "immunological cocktail" in the assay." Cancers vol. 5,4 (2013): 1739-47. doi: https://doi.org/10.3390/cancers5041739
Uhr JW. The clinical potential of circulating tumor cells; the need to incorporate a modern "immunological cocktail" in the assay. Cancers (Basel). 2013 Dec 13;5(4):1739-47. doi: 10.3390/cancers5041739. PMID: 24351672; PMCID: PMC3875962.
Copy Download .nbib Format: NLM
GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity.

Frontiers in immunology

Hastings KT.
PMID: 24409178
Front Immunol. 2013 Dec 04;4:429. doi: 10.3389/fimmu.2013.00429.

The MHC class II-restricted antigen processing pathway generates peptide:MHC complexes in the endocytic pathway for the activation of CD4(+) T cells. Gamma-interferon-inducible lysosomal thiol reductase (GILT) reduces protein disulfide bonds in the endocytic compartment, thereby exposing buried epitopes for...

Cite
Hastings KT. GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity. Front Immunol. 2013;4:429doi: 10.3389/fimmu.2013.00429.
Hastings, K. T. (2013). GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity. Frontiers in immunology, 4429. https://doi.org/10.3389/fimmu.2013.00429
Hastings, Karen Taraszka. "GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity." Frontiers in immunology vol. 4 (2013): 429. doi: https://doi.org/10.3389/fimmu.2013.00429
Hastings KT. GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity. Front Immunol. 2013 Dec 04;4:429. doi: 10.3389/fimmu.2013.00429. PMID: 24409178; PMCID: PMC3885806.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 3774 entries